Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.

Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS.Research by ...

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

A line chart showing valuation multiples Novo Nordisk’s fortunes turned last December when its hotly anticipated treatment CagriSema failed to meet expectations on weight loss and tolerability.

In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide have made headlines for their impressive ability to promote weight loss and improve ... such as ...